secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001493152-26-016979
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma signs LOI to acquire automotive supplier DCS for $30M; DCS had $200M+ revenue in FY2025
--------------------------------------------------------------------------------

- Purchase price of $30M cash for 100% of DCS; DCS generated >$200M revenue and >$22M adjusted EBITDA in FY2025 (unaudited).
- DCS is a tier-one auto supplier with 310 patents, 11 global facilities, serving 150+ vehicle platforms across major OEMs.
- Management from Lakewood & Company (100+ years auto experience) to bolster DCS leadership; deal subject to due diligence and audit.
- RBW Capital Partners is exclusive financial advisor; Dawson James Securities will provide brokerage services for the acquisition.
- Aspire plans to become a diversified, high-revenue enterprise; no definitive agreement executed yet and no assurance of completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226016979/0001493152-26-016979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226016979/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-016979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer